Johnson & Johnson stock forecast
Johnson & Johnson's weighted forecast is $251.90 in October 2029. It hinges on replacing STELARA while MedTech and legal cash demands stay under control.
Where could Johnson & Johnson's shares be by October 2029?
The forecast points to a near-term decline before a modest recovery. The weighted price is $229.07 in October 2027, a 6% loss with dividends. It rises to $239.91 in October 2028, a 1% gain. By October 2029, it reaches $251.90, an 8% gain.
The central case has 53% probability. The bear case has 27%, while the bull case has 20%. The October 2029 range runs from $143.33 in the bear case to $384.60 in the bull case. Today's price is $248.61, so the forecast sees moderate expected returns but substantial execution risk.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 27% | 175.77 (-27%) | 154.15 (-34%) | 143.33 (-36%) |
| Base | 53% | 236.34 (-3%) | 246.31 (+4%) | 257.13 (+10%) |
| Bull | 20% | 281.75 (+16%) | 338.71 (+41%) | 384.60 (+62%) |
| Weighted | 100% | 229.07 (-6%) | 239.91 (+1%) | 251.90 (+8%) |
What this means. The weighted row is the probability-based average of the bear, base, and bull cases, so it is not a prediction that the shares will follow that exact price.
What has to go right for Johnson & Johnson—and what could go wrong?
The bear case holds earnings near $26,520 million in the first year and then allows only slight improvement, as replacement sales lag, biosimilars pressure margins and separation costs persist. TREMFYA replaced only about 35% of STELARA's 2025 revenue decline, while Q3 MedTech growth was 2.5%. The bull case reaches $36,500 million by 2029, requiring faster TREMFYA, oncology and neuroscience growth plus expanding margins. J&J's $55 billion investment programme supports that possibility, but does not make it the central outcome.
The bear case assumes biosimilar erosion outpaces replacement, MedTech stays uneven and separation costs pressure margins. Talc payments then limit buybacks, while weaker earnings durability compresses the P/E. The price falls to $175.77 in October 2027 and $143.33 by October 2029. Its 27% probability reflects the combined downside assigned to earnings and valuation, while dividends and shares provide only limited protection.
How much cash does Johnson & Johnson really make?
Profit records accounting income; cash flow records money collected and paid. J&J’s operating cash flow was $24,530 million in 2025, while free cash flow after capital spending was $19,536 million. A sale may be recorded before the customer pays, and inventory may consume cash before it is sold.
| 2025 | 2024 | 2023 | Jan 2023 | Jan 2022 | |
|---|---|---|---|---|---|
| Cash from operations | 24,530 | 24,266 | |||
| − Capital spending | 4,994 | 4,598 | 4,381 | 3,706 | 3,338 |
| = Free cash flow | 19,536 | 19,668 | |||
| − Stock pay | 1,354 | 1,176 | 1,087 | 1,028 | 1,038 |
| = Real free cash flow | 18,182 | 18,492 | |||
| Real free cash flow, % of revenue | 19.3% | 20.8% |
What this means. The company's free cash flow is higher because it leaves out 162 million dollars of cash costs in 2025 and 174 million dollars in 2024 that we count.
What does Johnson & Johnson's stock price pay for in earnings and cash?
| Today (Oct 14, 2026) | |
|---|---|
| Share price | 248.61 |
| Market value (calculated) | 599,125 |
| Enterprise value (calculated) | 627,403 |
| P/E, last 12 months (calculated) | 37.7x |
| P/E, next 12 months (calculated) | 20.1x |
| Real free cash flow yield (calculated) | 3.0% |
What this means. The share price is from the market's close on October 13, even though the table is dated October 14.